title: Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.
abstract: Somatic mutations in TET2 occur in patients with myeloproliferative neoplasms and other hematologic malignancies. It has been suggested that TET2 is a tumor suppressor gene and mutations in TET2 precede the acquisition of JAK2-V617F. To examine the order of events, we performed colony assays and genotyped TET2 and JAK2 in individual colonies. In 4 of 8 myeloproliferative neoplasm patients, we found that some colonies with mutated TET2 carried wild-type JAK2, whereas others were JAK2-V617F positive, indicating that TET2 occurred before JAK2-V617F. One of these patients carried a germline TET2 mutation. However, in 2 other patients, we obtained data compatible with the opposite order of events, with JAK2 exon 12 mutation preceding TET2 mutation in one case. Finally, in 2 of 8 patients, the TET2 and JAK2-V617F mutations defined 2 separate clones. The lack of a strict temporal order of occurrence makes it unlikely that mutations in TET2 represent a predisposing event for acquiring mutations in JAK2.
authors.affiliation: Department of Biomedicine, Experimental Hematology, University Hospital Basel, Hebelstr 20, 4031 Basel, Switzerland.
authors.forename: Franz X
authors.initials: FX
authors.lastname: Schaub
authors.forename: Renate
authors.initials: R
authors.lastname: Looser
authors.forename: Sai
authors.initials: S
authors.lastname: Li
authors.forename: Hui
authors.initials: H
authors.lastname: Hao-Shen
authors.forename: Thomas
authors.initials: T
authors.lastname: Lehmann
authors.forename: Andre
authors.initials: A
authors.lastname: Tichelli
authors.forename: Radek C
authors.initials: RC
authors.lastname: Skoda
mesh_terms: D000368:Aged; D002469:Cell Separation / Q000379:methods; D002999:Clone Cells / Q000378:metabolism / Q000473:pathology*; D004252:DNA Mutational Analysis; D004268:DNA-Binding Proteins / Q000235:genetics*; D049308:Dioxygenases; D018450:Disease Progression; D005260:Female; D020022:Genetic Predisposition to Disease; D019337:Hematologic Neoplasms / Q000235:genetics / Q000473:pathology; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000502:physiology; D009196:Myeloproliferative Disorders / Q000235:genetics* / Q000473:pathology; D020641:Polymorphism, Single Nucleotide / Q000502:physiology; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D014407:Tumor Cells, Cultured
chemical_list: D004268:DNA-Binding Proteins; D011518:Proto-Oncogene Proteins; D049308:Dioxygenases; C541081:TET2 protein, human; C507924:JAK2 protein, human; D053614:Janus Kinase 2